Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 159,693 shares of the biopharmaceutical company's stock after buying an additional 7,295 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Gilead Sciences were worth $14,751,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors also recently bought and sold shares of GILD. Bellevue Group AG increased its holdings in shares of Gilead Sciences by 18.2% in the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company's stock valued at $3,859,000 after purchasing an additional 7,093 shares during the last quarter. Quantinno Capital Management LP raised its holdings in shares of Gilead Sciences by 149.5% during the 3rd quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company's stock worth $6,843,000 after acquiring an additional 48,910 shares during the period. McAdam LLC boosted its position in shares of Gilead Sciences by 16.7% during the 4th quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company's stock valued at $2,344,000 after acquiring an additional 3,627 shares during the last quarter. IRON Financial LLC purchased a new stake in shares of Gilead Sciences in the third quarter valued at about $830,000. Finally, Capital Investment Advisors LLC increased its position in Gilead Sciences by 2.6% during the fourth quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company's stock worth $35,793,000 after purchasing an additional 9,791 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on GILD. Citigroup initiated coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They issued a "buy" rating and a $125.00 target price on the stock. Mizuho upped their price objective on Gilead Sciences from $90.00 to $100.00 and gave the company an "outperform" rating in a report on Thursday, November 21st. Morgan Stanley raised Gilead Sciences from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $87.00 to $113.00 in a research note on Friday, January 10th. The Goldman Sachs Group upped their price target on Gilead Sciences from $74.00 to $84.00 and gave the company a "neutral" rating in a research note on Thursday, November 7th. Finally, Piper Sandler boosted their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $98.39.
Read Our Latest Analysis on GILD
Insider Buying and Selling at Gilead Sciences
In related news, insider Merdad Parsey sold 164,211 shares of the business's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares in the company, valued at $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 572,824 shares of company stock worth $53,611,715 over the last ninety days. Corporate insiders own 0.16% of the company's stock.
Gilead Sciences Stock Down 2.0 %
Shares of GILD stock traded down $2.00 during trading hours on Friday, reaching $96.04. 7,182,199 shares of the stock were exchanged, compared to its average volume of 6,866,207. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $100.51. The business's fifty day moving average is $93.04 and its two-hundred day moving average is $86.76. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The firm has a market capitalization of $119.69 billion, a P/E ratio of 1,067.11, a P/E/G ratio of 1.25 and a beta of 0.18.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to analysts' expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company's revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the previous year, the company earned $2.29 EPS. As a group, research analysts expect that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
